Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis
Leukemia,  Clinical Article

Teuffel O et al. – DEX in induction therapy for children with ALL is more efficacious than PRED. However, DEX is also associated with more toxicity, and currently it remains unclear whether short-term superiority of DEX will also result in better overall survival.

Methods

  • Systematic review and meta-analysis compared efficacy and toxicity of DEX versus PRED for induction therapy in childhood ALL
  • Searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and PRED during induction therapy for childhood ALL
  • Meta-analysis
  • 8 studies eligible for inclusion

Results
  • DEX, in comparison with PRED, reduced events (that is, death from any cause, refractory or relapsed leukemia, or second malignancy; risk ratio (RR) 0.80; 95% CI, 0.68–0.94) and central nervous system relapse (RR 0.53; 95% CI, 0.44–0.65), but did not alter bone marrow relapse (RR 0.90; 95% CI, 0.69–1.18) or overall mortality (RR 0.91; 95% CI, 0.76–1.09)
  • Patients receiving DEX had higher risk of mortality during induction (RR 2.31; 95% CI, 1.46–3.66), neuro-psychiatric AEs (RR 4.55; 95% CI, 2.45–8.46) and myopathy (RR 7.05; 95% CI, 3.00–16.58)
  • No statistically significant difference in risk of osteonecrosis, sepsis, fungal infection, diabetes or pancreatitis
  • DEX in induction therapy for children with ALL is more efficacious than PRED
  • No statistically significant difference in risk of osteonecrosis, sepsis, fungal infection, diabetes or pancreatitis

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List